Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 8/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | LTB4R | Q15722 | 2/20 | 0.40 |
| ▸ | LTB4R2 | Q9NPC1 | 2/20 | 0.40 |
| ▸ | DHFR | P00374 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | PPARG | P37231 | 2/20 | 0.38 |
| ▸ | GCGR | P47871 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6035760 | 0.92 | SMN1; SMN2 (0.43) | PPARDSMN1; SMN2KDM4ELMNAHPGD | |
| SCHEMBL6036240 | 0.90 | LTB4R (0.42) | PPARDSMN1; SMN2KDM4ELMNALTB4R | |
| SCHEMBL6034609 | 0.90 | SMN1; SMN2 (0.43) | PPARDSMN1; SMN2KDM4ELMNAHPGD | |
| SCHEMBL6034561 | 0.90 | SMN1; SMN2 (0.38) | PPARDSMN1; SMN2KDM4ELMNADHFR | |
| SCHEMBL6035948 | 0.89 | PPARG (0.42) | PPARDSMN1; SMN2KDM4ELMNAHPGD | |
| SCHEMBL6034497 | 0.89 | PPARG (0.40) | PPARDSMN1; SMN2KDM4EPPARGGCGR | |
| SCHEMBL6035713 | 0.89 | PPARG (0.43) | PPARDPPARGGCGR | |
| SCHEMBL1633062 | 0.88 | PPARG (0.41) | PPARDSMN1; SMN2KDM4ELMNAPPARG | |
| SCHEMBL6034680 | 0.88 | LTB4R (0.44) | PPARDSMN1; SMN2KDM4ELMNALTB4R | |
| SCHEMBL6035939 | 0.88 | SMN1; SMN2 (0.44) | PPARDSMN1; SMN2KDM4ELMNAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060148858-A1 | 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148858-A1 | 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity | GPR119, SLC5A1, CYP4B1 | PPARD 2488/4885SMN1; SMN2 4408/4885KDM4E 509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.